Dr. Johnson on the Limitations of Biomarkers in Melanoma
Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.
Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.
Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.
R. Lor Randall, MD, FACS, discusses research examining ALDH1A1 and CD44, potential markers of osteosarcoma stem cells, and how further research may be warranted with…
Benjamin Tomlinson, MD, discusses the first-line approval of luspatercept and other ongoing research in low-risk MDS.
Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.
Drs Merkow and Connell discuss the use of HAI therapy for patients with colorectal cancer.
Joshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Neal Shore, MD, FACS, discusses the importance of a multidisciplinary team in light of recent developments in urologic oncology.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.